Angiotensin receptor blockers in heart failure after the ELITE II trial
AUTOR(ES)
Willenheimer, Ronnie
FONTE
BioMed Central
RESUMO
Specific blockers of the angiotensin type1 receptor, angiotensin receptor blockers (ARBs), have been introduced as an alternative to angiotensin-converting enzyme inhibitors (ACEi) for the treatment of heart failure. In comparison with ACEi, ARBs are better tolerated and have similar effects on haemodynamics, neurohormones and exercise capacity. Early studies have suggested that ARBs might have a superior effect on mortality. However, the first outcome trial, ELITE II (Losartan Heart Failure Survival Study), did not show any significant difference between losartan and captopril in terms of mortality or morbidity. This commentary outlines the role of ARBs in the treatment of heart failure.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=59604Documentos Relacionados
- ACE inhibitors and angiotensin II receptor blockers: little difference
- Angiotensin-II–receptor blockers and nephropathy in patients with type 2 diabetes
- Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure. Role of kinins and angiotensin II type 2 receptors.
- Beta-blockers in severe congestive heart failure
- Congestive heart failure in normotensive man. Haemodynamics, renin, and angiotensin II blockade.
